Loading...
Publication
O potencial dos inibidores das histonas desacetilases no tratamento do cancro da próstata
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 3.26 MB | Adobe PDF |
Authors
Abstract(s)
Introdução: O carcinoma da próstata é uma das neoplasias mais prevalentes no sexo masculino a nível mundial, com maior incidência em países desenvolvidos, onde a utilização de técnicas de prevenção secundária é mais disseminada. Apesar dos avanços terapêuticos, os casos de cancro metastático, recorrente ou com mecanismos de resistência continuam a representar um desafio médico significativo. Para além das mutações genéticas, as alterações epigenéticas, como a desacetilação das histonas, desempenham um papel crucial na progressão tumoral. Os inibidores das histonas desacetilases têm demonstrado efeitos terapêuticos promissores, estando já aprovados para o tratamento de várias neoplasias. Atualmente, estão a ser investigados em ensaios clínicos com o objetivo de otimizar o tratamento do carcinoma da próstata. Objetivos: A presente dissertação tem como objetivo analisar e destacar a relevância do potencial terapêutico dos inibidores das histonas desacetilases, quer em monoterapia, quer em combinação com outros agentes, no tratamento de carcinomas da próstata refratários às terapêuticas convencionais. Metodologia: A pesquisa bibliográfica foi conduzida na base de dados PubMed, entre agosto de 2023 e agosto de 2024, incluindo artigos em inglês sem restrições temporais, tendo sido elegidos, sempre que possível, os estudos mais recentes. Após uma análise criteriosa, foram selecionados os materiais de maior relevância para o tema. Conclusão e perspetivas futuras: Os inibidores das histonas desacetilases têm evidenciado efeitos promissores, sobretudo no contexto das neoplasias hematológicas. No entanto, a sua utilização em monoterapia tem apresentado resultados limitados em tumores sólidos, como o carcinoma da próstata, devido à emergência de mecanismos de resistência, respostas terapêuticas parciais e efeitos adversos que comprometem a continuidade do tratamento. Em contrapartida, a combinação destes inibidores com agentes quimioterapêuticos ou outros fármacos específicos tem demonstrado uma eficácia superior, revelando-se como uma abordagem promissora para doentes que esgotaram outras opções terapêuticas. Esta estratégia combinada proporciona uma nova esperança para casos avançados, com o potencial de melhorar a resposta ao tratamento e prolongar a sobrevida dos pacientes. Assim, torna-se imperativo continuar a investigação nesta área, dado que poderá contribuir significativamente para a obtenção de melhores resultados nos ensaios clínicos.
Introduction: Prostate carcinoma is one of the most prevalent cancers among men worldwide, with a higher incidence in developed countries where the use of secondary prevention techniques is more widespread. Despite therapeutic advances, cases of metastatic, recurrent, or resistant cancer continue to represent a significant medical challenge. In addition to genetic mutations, epigenetic alterations, such as histone deacetylation, play a crucial role in tumor progression. Histone deacetylase inhibitors have shown promising therapeutic effects and are already approved for the treatment of various cancers. They are currently being investigated in clinical trials with the aim of optimizing the treatment of prostate carcinoma. Objectives: This dissertation aims to analyze and highlight the relevance of the therapeutic potential of histone deacetylase inhibitors, whether in monotherapy or in combination with other agents, in the treatment of prostate carcinomas refractory to conventional therapies. Methodology: A bibliographic search was conducted in the PubMed database between August 2023 and August 2024, including articles in english with no temporal restrictions, prioritizing the most recent studies whenever possible. After careful analysis, the most relevant materials were selected for the topic at hand. Conclusion and Future Perspectives: Histone deacetylase inhibitors have shown promising effects, particularly in the context of hematologic malignancies. However, their use in monotherapy has shown limited results in solid tumors, such as prostate carcinoma, due to the emergence of resistance mechanisms, partial therapeutic responses, and adverse effects that compromise treatment continuity. On the other hand, the combination of these inhibitors with chemotherapeutic agents or other specific drugs has demonstrated superior efficacy, representing a promising approach for patients who have exhausted other therapeutic options. This combined strategy provides new hope for advanced cases, with the potential to improve treatment response and prolong patient survival. Therefore, it is imperative to continue research in this area, as it may significantly contribute to achieving better results in clinical trials.
Introduction: Prostate carcinoma is one of the most prevalent cancers among men worldwide, with a higher incidence in developed countries where the use of secondary prevention techniques is more widespread. Despite therapeutic advances, cases of metastatic, recurrent, or resistant cancer continue to represent a significant medical challenge. In addition to genetic mutations, epigenetic alterations, such as histone deacetylation, play a crucial role in tumor progression. Histone deacetylase inhibitors have shown promising therapeutic effects and are already approved for the treatment of various cancers. They are currently being investigated in clinical trials with the aim of optimizing the treatment of prostate carcinoma. Objectives: This dissertation aims to analyze and highlight the relevance of the therapeutic potential of histone deacetylase inhibitors, whether in monotherapy or in combination with other agents, in the treatment of prostate carcinomas refractory to conventional therapies. Methodology: A bibliographic search was conducted in the PubMed database between August 2023 and August 2024, including articles in english with no temporal restrictions, prioritizing the most recent studies whenever possible. After careful analysis, the most relevant materials were selected for the topic at hand. Conclusion and Future Perspectives: Histone deacetylase inhibitors have shown promising effects, particularly in the context of hematologic malignancies. However, their use in monotherapy has shown limited results in solid tumors, such as prostate carcinoma, due to the emergence of resistance mechanisms, partial therapeutic responses, and adverse effects that compromise treatment continuity. On the other hand, the combination of these inhibitors with chemotherapeutic agents or other specific drugs has demonstrated superior efficacy, representing a promising approach for patients who have exhausted other therapeutic options. This combined strategy provides new hope for advanced cases, with the potential to improve treatment response and prolong patient survival. Therefore, it is imperative to continue research in this area, as it may significantly contribute to achieving better results in clinical trials.
Description
Keywords
Cancro da Próstata Histonas Desacetilases Inibidores das Histonas Desacetilases Mecanismos Epigenéticos Recetor de Androgénios